Humanigen Inc HGEN:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 09/23/22 EDT
0.18quote price arrow up+0.01 (+4.10%)
Volume
395,604
Close
0.173quote price arrow up+0.0191 (+12.41%)
Volume
3,705,386
52 week range
0.15 - 8.38
Loading...
  • Open0.15
  • Day High0.177
  • Day Low0.1476
  • Prev Close0.1539
  • 52 Week High8.38
  • 52 Week High Date11/04/21
  • 52 Week Low0.15
  • 52 Week Low Date09/22/22

Key Stats

  • Market Cap17.93M
  • Shares Out103.66M
  • 10 Day Average Volume3.88M
  • Dividend-
  • Dividend Yield-
  • Beta-0.91
  • YTD % Change-95.35

KEY STATS

  • Open0.15
  • Day High0.177
  • Day Low0.1476
  • Prev Close0.1539
  • 52 Week High8.38
  • 52 Week High Date11/04/21
  • 52 Week Low0.15
  • 52 Week Low Date09/22/22
  • Market Cap17.93M
  • Shares Out103.66M
  • 10 Day Average Volume3.88M
  • Dividend-
  • Dividend Yield-
  • Beta-0.91
  • YTD % Change-95.35

RATIOS/PROFITABILITY

  • EPS (TTM)-2.40
  • P/E (TTM)-0.07
  • Fwd P/E (NTM)-0.30
  • EBITDA (TTM)-148.204M
  • ROE (TTM)-2,165.43%
  • Revenue (TTM)4.14M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-3,659.98%
  • Debt To Equity (MRQ)-50.68%

EVENTS

  • Earnings Date11/10/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Humanigen Inc

 

Content From Our Affiliates

Profile

MORE
Humanigen, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing its portfolio of Humaneered anti-inflammatory immunology and immuno-oncology monoclonal antibodies. Its Humaneered technology platform offers a method for converting existing antibodies into engineered human antibodies designed for therapeutic use, primarily with acute and chronic conditions. The Company’s lead product candidate, lenzilumab, and its other two product...
Cameron Durrant M.D.
Chairman of the Board, Chief Executive Officer
Timothy Morris CPA
Chief Financial Officer, Chief Operating Officer
Address
830 MORRIS TURNPIKE, 4TH FLOOR
Short Hills, NJ
07078
United States

Top Peers

SYMBOLLASTCHG%CHG
PULM
Pulmatrix Inc
3.61-0.10-2.70%
OPGN
OpGen Inc
0.3872-0.0284-6.8335%
FRTX
Fresh Tracks Therapeutics Inc
1.87+0.05+2.75%
HSTO
Histogen Inc
1.41+0.04+2.55%
ABEO
Abeona Therapeutics Inc
3.03-0.22-6.77%